The Journal of Psychiatric Research is retracting a 2010 paper claiming to show a relationship between quetiapine (Seroquel) and certain lab tests and brain scans, after it turns out the brain images were either unreliable or invalid.
Here’s the notice for “Relationship between dopamine D2 receptor occupancy, clinical response, and drug and monoamine metabolites levels in plasma and cerebrospinal fluid. A pilot study in patients suffering from first-episode schizophrenia treated with quetiapine”:
This article has been retracted: please see Elsevier Policy on Article Withdrawal (http://www.elsevier.com/locate/withdrawalpolicy).
This article has been retracted at the request of the Editors
Key results are based on invalid data, according to a recent notification by the authors. The findings of the article are significantly related to dopamine D2 receptor occupancy data, obtained from a Positron Emission Tomography (PET) scan in five individuals. According to new evidence, PET data of two out of these individuals did not show a reliable signal at all, while the PET results of the remaining three subjects are partly invalid. As a result, the reported findings are most likely incorrect. Journal of Psychiatric Research is dedicated to the highest scientific standards, therefore, this article has been retracted. The Editors regret if any misleading conclusions have been drawn from this publication, and apologies are offered to the readers of the journal.
The study was partially funded by Seroquel maker AstraZeneca, which paid more than half a billion dollars to the U.S. government last year to settle charges it paid “kickbacks to doctors as part of an illegal scheme to market [Seroquel] for unapproved uses.” It has been cited six times, according to Thomson Scientific’s Web of Knowledge.
It’s not clear how the problems with the data came to the attention of the authors. We tried contacting the editors of the journal, and the corresponding author, and will update with anything we hear back.
Hat tip: Clare Francis
Like this:Be the first to like this.